Olanzapine and cognitive-behavioural group therapy in borderline personality disorder;Olanzapina y terapia grupal cognitivo-conductual en trastorno límite de la personalidad

Actas Espanolas de Psiquiatria

Volumn 29, Issue 2, 2001, Pages 85-90

  Soler, J ^a   Campins, M J ^a   Perez V ^a   Puigdemont, D ^a   Perez Blanco F ^a   Alvarez E ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Borderline personality; Cognitive behaviour therapy; Olanzapine

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE;

ADULT; ARTICLE; BORDERLINE STATE; CASE REPORT; COGNITIVE THERAPY; FEMALE; GROUP THERAPY; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; PILOT STUDY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PILOT PROJECTS; PIRENZEPINE; PSYCHOTHERAPY, GROUP;

EID: 0035290334     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association; 1994.
2. Hawton K. Deliberate self harm: systematic review of efficacy of psychosocial and pharmacological treatmentes in preventing repetition. Br Med J 1998; 317:441-7.
3. Coccaro EE. Clinical outcome of psychopharmacologic treatment of Borderline and Schizotypal personality disordered subjects. J Clin Psychiatry 1998;59 (Supl 1):30-5.
4. Stein G. Drug treatment of personality disorders. Br J Psychiatry 1992;161:167-84.
5. Jensen HV, Anderson J. An open, non-comparative study of amoxapine in borderline disorders. Acta Psychiatr Scand 1989;79:89-93.
6. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993;34:402-5.
7. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998;59:103-7.
8. Szigethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia (letter). J Clin Psychopharmacol 1997;17:326-7.
9. Khouzam HR, Donnelly NJ. Remission of self-mutilation in a patient with borderline personality during risperidone therapy (letter). J Nerv Mental Dis 1997; 185:348-9.
10. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Investigation Drugs 1993;4:281-93.
11. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(Supl 10):28-36.
12. Mann JJ. Violence and Aggression En: Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1996.
13. Beck AT, Freeman A, & Associates. Cognitive therapy of personality disorders. New York, NY: Guilford Press; 1990.
14. Young JE. Cognitive therapy for personality disorders: A Schema-focused approach. Sarasota, Florida: Professional Resource Exchange; 1990.
15. Linehan MM. Cognitive-Behavioural treatment of borderline personality disorder. New York, NY: Guilford Press; 1993.
16. Linehan MM. Skills training manual for treating borderline personality disorder. New York, NY: Guilford Press; 1993.
17. Linehan MM, Amstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-Behavioral Treatment of Chronically Parasuicidal Borderline Patients. Arch Gen Psychiatry 1991;48:1060-4.
18. Organización Mundial de la Salud (OMS). Examen Internacional de los Transtornos de la Personalidad (IPDE) - módulo DSM-IV. Madrid: Meditor; 1996.
19. McNair DM, Lorr M, Droppleman LF. Profile of mood states. Manual and Forms. San Diego, California: Educational and Industrial Testing Service; 1981.
20. Guy W. ECDEU Assessment for psychopharmacology, revised. US Dept Health, Education and Welfare Publication (ADM). Rockville, Maryland: National Institute of Mental Health; 1976.
21. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Report 1962;10:799-812.
22. Hamilton MA. Rating Scale Depression. J Neurol Noursering Psychiatry 1960;23:56-62.
23. Cornelius JR, Soloff PH, Perel JM, Richard F, Ulrich MS. Continuation pharmacoterapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993;150:1843-8.
24. Soloff PH, Siever L, Cowdry R, Kocsis, JH. Evaluation of pharmacologic treatments in personality disorders. Clinical evaluations of psychotropic drugs: Principles and Guidelines. New York, NY: Raven Press; 1994. p. 651-73.
25. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry 1986;43:691-7.
26. Hengeveld MW, Jonker DJ, Rooijmans HG. A pilot study of a short cognitive-behavioral group treatment for female recurrent suicide attempters. Int J Psychiatry Med 1996;26:83-91.
27. Cowdry RW, Gardner DL. Pharmacoterapy of borderline personality disorder. Arch Gen Psychiatry 1988; 45:111-9.
28. Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985;142:98-100.
29. Silva H, Jerez S, Paredes A, Salvo J, Rentería P, Ramirez A, Montes C. Fluoxetine in the treatment of borderline personality disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997;25:391-5.